Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.

Journal of medicinal chemistry - 27 May 2021

Sheffels Erin, Kortum Robert L

Abstract excerpt

In RTK/RAS-mutated cancers, therapeutic resistance is driven by rebound activation of multiple RTKs; broad inhibition of RTK signaling can potentially delay therapeutic resistance for a majority of patients. A new SOS1 inhibitor, BI-3406, broadly inhibits proximal RTK signaling will greatly expand the efficacy of therapies used to treat RTK/RAS-mutated cancers.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Neoplasms
Share to Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to ras Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Signal Transduction

Share to SOS1 Protein

Source

Identifiers

PMID: 33961431
DOI: 10.1021/acs.jmedchem.1c00698

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.PMID 33961431Read ↗

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinomaSemantic proximity Read ↗

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Semantic proximity Read ↗

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read ↗

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read ↗

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.Semantic proximity Read ↗

Cancer therapy based on oncogene addictionSemantic proximity Read ↗

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.Semantic proximity Read ↗

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity Read ↗

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors.Semantic proximity Read ↗

The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.